
|Videos|July 21, 2023
Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
AAO 2025: Ashkan Abbey on the outcomes of EYP-1901 for AMD and DME
2
Leadership in action during the 2025 AAO named lectures
3
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
4
Empowerment through education: Q&A with Inder Paul Singh, MD
5